Journal of Translational and Practical Medicine regularly publishes internationally qualified issues in the field of Medicine in the light of up-to-date information.

EndNote Style
Current epidemiology, risk factors, classification and pathophysiology in central serous chorioretinopathy
Central serous chorioretinopathy (CSCR) is one of the important posterior segment diseases that threaten vision in middle-aged men. While the incidence in men is 9.9 per 100,000, it is 1.7 per 100,000 in women. Fellow eyes of patients with CSCR are usually asymptomatic. CSCR can be acute, recurrent, or chronic. Many risk factors for CSCR have been identified, such as genetic, environmental, drug, and other diseases. Optical coherence tomography, fundus autofluorescence, fundus fluorescein angiography, and indocyanine green angiography are used for diagnosis.

1. Gass JD. Pathogenesis of disciform detachment of theneuroepithelium. Am J Ophthalmol. 1967;63(3):Suppl:1-139.
2. Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Centralserous chorioretinopathy. Acta Ophthalmol. 2008;86(2):126-145.
3. Kaye R, Chandra S, Sheth J, Boon CJF, Sivaprasad S, Lotery A.Central serous chorioretinopathy: An update on risk factors,pathophysiology and imaging modalities. Prog Retin Eye Res.2020;79:100865.
4. Spaide RF, Gemmy Cheung CM, Matsumoto H, et al. Venousoverload choroidopathy: a hypothetical framework for centralserous chorioretinopathy and allied disorders. Prog Retin Eye Res.2022;86:100973.
5. Lehmann M, Bousquet E, Beydoun T, Behar-CohenF. PACHYCHOROID: an inherited condition? Retina.2015;35(1):10-16.
6. Gäckle HC, Lang GE, Freissler KA, Lang GK. [Central serouschorioretinopathy. Clinical, fluorescein angiography anddemographic aspects]. Ophthalmologe. 1998;95(8):529-533.
7. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. Theincidence of central serous chorioretinopathy in Olmsted County,Minnesota, 1980-2002. Ophthalmology. 2008;115(1):169-173.
8. Spaide RF, Campeas L, Haas A, et al. Central serouschorioretinopathy in younger and older adults. Ophthalmology.1996;103(12):2070-2079; discussion 2079-2080.
9. Tittl MK, Spaide RF, Wong D, et al. Systemic findings associatedwith central serous chorioretinopathy. Am J Ophthalmol.1999;128(1):63-68.
10. Pan CK, Vail D, Bhattacharya J, Cao M, Mruthyunjaya P. Theeffect of obstructive sleep apnea on absolute risk of central serouschorioretinopathy. Am J Ophthalmol. 2020;218:148-155.
11. Tsai DC, Chen SJ, Huang CC, et al. Epidemiology of idiopathiccentral serous chorioretinopathy in Taiwan, 2001-2006: apopulation-based study. PLoS One. 2013;8(6):e66858.
12. Kim YC, Kim SD, Kim KS. A case of idiopathic centralserous chorioretinopathy in a 12-year-old male treated withbevacizumab. Korean J Ophthalmol. 2012;26(5):391-393.
13. Schatz H, Madeira D, Johnson RN, McDonald HR. Central serouschorioretinopathy occurring in patients 60 years of age and older.Ophthalmology. 1992;99(1):63-67.
14. Chan WM, Lim TH, Pece A, Silva R, Yoshimura N. VerteporfinPDT for non-standard indications--a review of current literature.Graefes Arch Clin Exp Ophthalmol. 2010;248(5):613-626.
15. Kunavisarut P, Pathanapitoon K, van Schooneveld M, Rothova A.Chronic central serous chorioretinopathy associated with serousretinal detachment in a series of Asian patients. Ocul ImmunolInflamm. 2009;17(4):269-277.
16. How AC, Koh AH. Angiographic characteristics of acute centralserous chorioretinopathy in an Asian population. Ann Acad MedSingap. 2006;35(2):77-79.
17. Desai UR, Alhalel AA, Campen TJ, Schiffman RM, EdwardsPA, Jacobsen GR. Central serous chorioretinopathy in AfricanAmericans. J Natl Med Assoc. 2003;95(7):553-559.
18. Gilbert CM, Owens SL, Smith PD, Fine SL. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol.1984;68(11):815-820.
19. Baran NV, Gürlü VP, Esgin H. Long-term macular functionin eyes with central serous chorioretinopathy. Clin ExperimentOphthalmol. 2005;33(4):369-372.
20. Ooto S, Tsujikawa A, Mori S, Tamura H, Yamashiro K, YoshimuraN. Thickness of photoreceptor layers in polypoidal choroidalvasculopathy and central serous chorioretinopathy. Graefes ArchClin Exp Ophthalmol. 2010;248:1077-1086.
21. Piccolino FC, De La Longrais RR, Manea M, Cicinelli S. Posteriorcystoid retinal degeneration in central serous chorioretinopathy.Retina. 2008;28(7):1008-1012.
22. Uyama M, Matsunaga H, Matsubara T, Fukushima I, Takahashi K,Nishimura T. Indocyanine green angiography and pathophysiologyof multifocal posterior pigment epitheliopathy. Retina.1999;19(1):12-21.
23. Tuncay FY, Gürelik G. Santral Seröz Koryoretinopati. Retina-Vitreus/Journal of Retina-Vitreous. 2010;18(2).
24. Gemenetzi M, De Salvo G, Lotery A. Central serouschorioretinopathy: an update on pathogenesis and treatment. Eye.2010;24(12):1743-1756.
25. Spaide RF, Ledesma-Gil G, Gemmy Cheung CM. intervortexvenous anastomosis in pachychoroid-related disorders. Retina.2021;41(5):997-1004.
26. Matsumoto H, Hoshino J, Mukai R, et al. Vortex vein anastomosisat the watershed in pachychoroid spectrum diseases. OphthalmolRetina. 2020;4(9):938-945.
27. Imanaga N, Terao N, Nakamine S, et al. Scleral thickness in centralserous chorioretinopathy. Ophthalmol Retina. 2021;5(3):285-291.
28. Sawaguchi S, Terao N, Imanaga N, et al. Scleral Thickness inSteroid-Induced Central Serous Chorioretinopathy. OphthalmolSci. 2022;2(2):100124.
29. Venkatesh P, Chawla R, Tripathy K, Singh HI, Bypareddy R.Scleral resection in chronic central serous chorioretinopathycomplicated by exudative retinal detachment. Eye Vis (Lond).2016;3(1):23.
30. Weenink AC, Borsje RA, Oosterhuis JA. Familial chronic centralserous chorioretinopathy. Ophthalmologica. 2001;215(3):183-187.
31. Miki A, Kondo N, Yanagisawa S, Bessho H, Honda S, Negi A.Common variants in the complement factor H gene confer geneticsusceptibility to central serous chorioretinopathy. Ophthalmology.2014;121(5):1067-1072.
32. de Jong EK, Breukink MB, Schellevis RL, et al. Chronic centralserous chorioretinopathy is associated with genetic variantsimplicated in age-related macular degeneration. Ophthalmology.2015;122(3):562-570.
33. Schubert C, Pryds A, Zeng S, et al. Cadherin 5 is regulatedby corticosteroids and associated with central serouschorioretinopathy. Human mutation. 2014;35(7):859-867.
34. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S, GroupCSCCCS. Risk factors for central serous chorioretinopathy: acase-control study. Ophthalmology. 2004;111(2):244-249.
35. Mansuetta CC, Mason III JO, Swanner J, et al. An associationbetween central serous chorioretinopathy and gastroesophagealreflux disease. Am J Ophthalmol. 2004;137(6):1096-1100.
36. Ahnoux-Zabsonre A, Quaranta M, Mauget-Faysse M. Prevalenceof Helicobacter pylori in central serous chorioretinopathy anddiffuse retinal epitheliopathy: a complementary study. J FrancaisD'ophtalmologie. 2004;27(10):1129-1133.
37. Carvalho-Recchia CA, Yannuzzi LA, Negrão S, et al.Corticosteroids and central serous chorioretinopathy.Ophthalmology. 2002;109(10):1834-1837.
38. Pizzimenti JJ, Daniel KP. Central serous chorioretinopathy afterepidural steroid injection. Pharmacotherapy: J Hum PharmacolDrug Therapy. 2005;25(8):1141-1146.
39. Kassam A-A, White W, Ling RH, Kitson JB. Loss of visual acuitydue to central serous retinopathy after steroid injection into theshoulder bursa. J Shoulder Elbow Surg. 2011;20(4):e5-e6.
40. Ezra N, Taban M, Behroozan D. Central serous chorioretinopathyassociated with topical corticosteroids in a patient with psoriasis.J Drugs Dermatol: JDD. 2011;10(8):918-921.
41. Baumal CR, Martidis A, Truong SN. Central serouschorioretinopathy associated with periocular corticosteroidinjection treatment for HLA-B27-associated iritis. ArchOphthalmol. 2004;122(6):926-928.
42. Ji Y, Li M, Zhang X, Peng Y, Wen F. Poor sleep quality is therisk factor for central serous chorioretinopathy. J Ophthalmol.2018;2018:9450297.
43. Tien PT, Lai CY, Lin CJ, et al. Increased risk of central serouschorioretinopathy among patients with nonorganic sleepdisturbance. J Ophthalmol. 2020;2020:1712503.
44. Jiang MS, Xu XL, Yang T, Li F, Zhang XD. Comparison ofchoroidal thickness in preeclamptic, healthy pregnant, andnonpregnant women: a systematic review and meta-analysis.Ophthalmic Res. 2019;62(1):1-10.
45. Mayo GL, Tolentino MJ. Images in clinical medicine. Centralserous chorioretinopathy in pregnancy. N Engl J Med.2005;353(7):e6.
46. Asensio-Sánchez VM, Rodríguez-Delgado B, García-HerreroE, Cabo-Vaquera V, García-Loygorri C. [Central serouschorioretinopathy as an extradigestive manifestation ofHelicobacter pylori gastric infection]. Arch Soc Esp Oftalmol. Mar2008;83(3):177-182.
47. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S. Riskfactors for central serous chorioretinopathy: a case-control study.Ophthalmology. 2004;111(2):244-249.
48. Karadağ MF. A new potential risk factor for central serouschorioretinopathy: blood pressure variability. Eye (Lond).2021;35(8):2190-2195.
49. Cassel GH, Brown GC, Annesley WH. Central serouschorioretinopathy: a seasonal variation? Br J Ophthalmol.1984;68(10):724-726.
50. Ersoz MG, Arf S, Hocaoglu M, Sayman Muslubas I, KaracorluM. Patient characteristics and risk factors for central serouschorioretinopathy: an analysis of 811 patients. Br J Ophthalmol.2019;103(6):725-729.
51. Yzer S, Fung AT, Barbazetto I, Yannuzzi LA, Freund KB. Centralserous chorioretinopathy in myopic patients. Arch Ophthalmol.2012;130(10):1339-1340.
52. Hunter RG. Epigenetic effects of stress and corticosteroids in thebrain. Front Cell Neurosci. 2012;6:18.
53. Chen S-N, Chen Y-C, Lian I. Increased risk of coronary heartdisease in male patients with central serous chorioretinopathy:results of a population-based cohort study. Br J Ophthalmol.2014;98(1):110-114.
54. Tsai D-C, Huang C-C, Chen S-J, et al. Central serouschorioretinopathy and risk of ischaemic stroke: a population-based cohort study. Br J Ophthalmol. 2012;96(12):1484-1488.
55. Tsai DC, Huang CC, Chen SJ, et al. Increased risk oferectile dysfunction among males with central serouschorioretinopathy-a retrospective cohort study. ActaOphthalmologica. 2013;91(7):666-671.
56. Tewari HK, Gadia R, Kumar D, Venkatesh P, Garg SP.Sympathetic-parasympathetic activity and reactivity in centralserous chorioretinopathy: a case-control study. InvestigativeOphthalmol Visual Sci. 2006;47(8):3474-3478.
57. Pierce KK, Lane RG. Central serous chorioretinopathy associatedwith the use of ephedra. Retinal Cases Brief Rep. 2009;3(4):376-378.
58. Aliferis K, Petropoulos I, Farpour B, Matter M, Safran A. Shouldcentral serous chorioretinopathy be added to the list of ocularside effects of phosphodiesterase 5 inhibitors? Ophthalmologica.2012;227(2):85-89.
59. Vance SK, Imamura Y, Freund KB. The effects of sildenafil citrateon choroidal thickness as determined by enhanced depth imagingoptical coherence tomography. Retina. 2011;31(2):332-335.
60. Bouzas EA, Karadimas P, Pournaras CJ. Central serouschorioretinopathy and glucocorticoids. Surv Ophthalmol.2002;47(5):431-448.
61. Ge G, Zhang Y, Zhang Y, Xu Z, Zhang M. Corticosteroids usageand central serous chorioretinopathy: a meta-analysis. GraefesArch Clin Exp Ophthalmol. 2020;258(1):71-77.
62. Imasawa M, Ohshiro T, Gotoh T, Imai M, Iijima H. Centralserous chorioretinopathy following vitrectomy with intravitrealtriamcinolone acetonide for diabetic macular oedema. ActaOphthalmologica Scandinavica. 2005;83(1):132-133.
63. Khairallah M, Kahloun R, Tugal-Tutkun I. Central serouschorioretinopathy, corticosteroids, and uveitis. Ocular ImmunolInflammation. 2012;20(2):76-85.
64. Han JM, Hwang J-M, Kim JS, Park KH, Woo SJ. Changes inchoroidal thickness after systemic administration of high-dosecorticosteroids: a pilot study. Invest Ophthalmol Visual Sci.2014;55(1):440-445.
65. Haimovici R, Rumelt S, Melby J. Endocrine abnormalities inpatients with central serous chorioretinopathy. Ophthalmology.2003;110(4):698-703.
66. Yannuzzi LA. Type-A behavior and central serouschorioretinopathy. Retina (Philadelphia, Pa.). 1987;7(2):111-131.
67. Yannuzzi LA. Type A behavior and central serouschorioretinopathy. Trans Am Ophthalmol Soc. 1986;84:799-845.
68. Conrad R, Weber NF, Lehnert M, Holz FG, Liedtke R, Eter N.Alexithymia and emotional distress in patients with centralserous chorioretinopathy. Psychosomatics. 2007;48(6):489-495.
69. Nattis A. Update on the Diagnosis and Treatment of CSC. RetinalPhysician, Volume: 12, Issue: October 2015, page(s): 18-21
Volume 2, Issue 1, 2023
Page : 20-25